GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Beyond Air Inc (FRA:48L) » Definitions » EV-to-EBITDA

Beyond Air (FRA:48L) EV-to-EBITDA : -0.23 (As of Sep. 26, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Beyond Air EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Beyond Air's enterprise value is €11.98 Mil. Beyond Air's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was €-51.70 Mil. Therefore, Beyond Air's EV-to-EBITDA for today is -0.23.

The historical rank and industry rank for Beyond Air's EV-to-EBITDA or its related term are showing as below:

FRA:48L' s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.2   Med: -3.49   Max: -0.09
Current: -0.24

During the past 10 years, the highest EV-to-EBITDA of Beyond Air was -0.09. The lowest was -13.20. And the median was -3.49.

FRA:48L's EV-to-EBITDA is ranked worse than
100% of 481 companies
in the Medical Devices & Instruments industry
Industry Median: 14.7 vs FRA:48L: -0.24

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-09-26), Beyond Air's stock price is €0.298. Beyond Air's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-1.518. Therefore, Beyond Air's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Beyond Air EV-to-EBITDA Historical Data

The historical data trend for Beyond Air's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beyond Air EV-to-EBITDA Chart

Beyond Air Annual Data
Trend Jun15 Jun16 Dec17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.70 -4.19 -3.00 -2.91 -1.11

Beyond Air Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.61 -0.85 -0.86 -1.11 -0.40

Competitive Comparison of Beyond Air's EV-to-EBITDA

For the Medical Devices subindustry, Beyond Air's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beyond Air's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Beyond Air's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Beyond Air's EV-to-EBITDA falls into.



Beyond Air EV-to-EBITDA Calculation

Beyond Air's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=11.978/-51.704
=-0.23

Beyond Air's current Enterprise Value is €11.98 Mil.
Beyond Air's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-51.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beyond Air  (FRA:48L) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Beyond Air's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.298/-1.518
=At Loss

Beyond Air's share price for today is €0.298.
Beyond Air's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.518.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Beyond Air EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Beyond Air's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Beyond Air Business Description

Traded in Other Exchanges
Address
900 Stewart Avenue, Suite 301, Garden City, New York, NY, USA, 11530
Beyond Air Inc is a clinical-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

Beyond Air Headlines

No Headlines